Cardiva raises $8.3m for vascular closure
This article was originally published in Clinica
Cardiva Medical, of Mountain View, California, has raised $8.3m in a series B financing. The company has developed technology for vascular closure that it says is safer and easier to use than other methods, such as manual compression or the use of biomaterials like collagen, sutures, staples or gels.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.